Parkinson's disease (PD) is one of the common chronic degenerative conditions of the
nervous system. There is currently no cure for PD, but a number of drugs offer benefits in …

Impulse control and related disorders (ICDs-RD) encompasses a heterogeneous group of
disorders that involve pleasurable behaviors performed repetitively, excessively, and …

Parkinson's Disease (PD) is an intractable disease resulting in localized neurodegeneration
of dopaminergic neurons of the substantia nigra pars compacta. Many current therapies of …

Parkinson's disease (PD) is the second most common neurodegenerative disease affecting
older adults, and it is approximately twice as common in males compared with females. 1 …

Introduction The randomized, double-blind phase (DBP) of the TOLEDO study confirmed the
efficacy of apomorphine infusion (APO) in reducing OFF time in PD patients with persistent …

Cellular quality control systems have gained much attention in recent decades. Among
these, autophagy is a natural self-preservation mechanism that continuously eliminates toxic …

Neuropsychiatric mood and motivation symptoms (depression, anxiety, apathy, impulse
control disorders) in Parkinson's disease (PD) are highly disabling, difficult to treat and …

Dopamine agonists (DAs) represent a mainstay of therapy for hyperprolactinemia and
prolactinomas. The widespread use of DAs, including bromocriptine, cabergoline and (in …

Background Impulse‐control and related behavioral disorders (ICBDs) significantly impact
the lives of Parkinson's disease (PD) patients and caregivers, with lasting consequences if …

Introduction Non-motor symptoms (NMS) affect patients with Parkinson's disease (PD) from
the prodromal to the advanced stages. NMS phenotypes greatly vary and have a huge …